The possible mechanisms include growth of CD19-negative cells, lineage switching, cellular gnawing, increased expression of (progressed death) PD-1 in leukemia cells, etc. Seven patients who relapsed after the first hCART19s infusion received a second hCART19s infusion. This evidence concerns the gene CD19 and leukemia.